I graduated from Swansea University in 2016 with a first-class degree in Medical Genetics and received the Jim Parry award. During my studies, I completed an industrial year at GSK, honing skills in various genetic toxicology assays. I pursued a PhD at Swansea University, focusing on genotoxic endpoint analysis and assay development with high content imaging. Here, as PGR representative, I organised the medical school PGR conference, fostering a passion for scientific communication and engagement. My work at Helix3 in the USA involved the GLP comet assay to support regulatory submissions and feasibility assessment of investigative/mechanistic studies. Currently employed at GSK, I have expanded my knowledge of the drug development pipeline, DNA damage assays, benchmark dose analysis, and data handling. Alongside this, I support junior scientists and continue work on mode and mechanism of action with promising use of deep learning for mining of high content image data. A UKEMS member since 2014, I joined the NUKEMS committee in May 2022 and became chair in July 2023.

I recently graduated from Brunel University London with a Bachelor’s in Biomedical Sciences, Genetics, and have started my PhD at Swansea University. Throughout my academic career, I had the incredible opportunity to intern in various laboratories and fields, including Molecular Medicine and Cellular Technology and the Republican Cancer Center in Uzbekistan, the Myogen Genetic Diseases and Diagnostic Centre in Turkey, and notably, a placement year at GSK in the Department of Genetic Toxicology and Photosafety. Here in Swansea, my PhD project involves optimizing an in vitro safety assessment, aligned with the 3R principle, focusing on cancer energy metabolism and using metabolic alterations as endpoints to detect genotoxicity.
I have been a member of the UKEMS since 2021, during which I presented my research on the genotoxic potential of NDMA in mice, using Flow Cytometry Pig-A and Micronucleus Assays. This work earned me the Best Overall Presentation Award during the UKEMS 2022 Conference in Harrogate.

I joined the NUKEMS Committee as Secretary in 2017 during my studies for my PhD on an exposure model in in vitro genotoxicity testing at Swansea University (supervised by past UKEMS President, Prof. Gareth Jenkins). Following my PhD, I worked on in vitro toxicology in drug development at Cardiff University before joining Imperial Brands as a Pre-Clinical Toxicologist in 2019. Since then, I have moved to focus on regulatory science, first as a Senior Regulatory Science Writer and now a Regulatory Scientific Strategy Manager. I became Chair of NUKEMS in April 2020, and rotated from this position in July 2023 into a Past Chair role, alongside joining the UKEMS Committee as an Ordinary Member. I have been a member of UKEMS since 2015 and am very grateful for the amazing support they offer to New Investigators, from opportunities to present their work, to a great selection of funding opportunities. I’m proud of the achievements of the NUKEMS Committee in supporting and enthusing early career scientists to date and to be a part of this.

In 2019 I completed my PhD at the University of Manchester (in collaboration with AstraZeneca). My research focussed on assessing the role of epigenetic factors in chromosome instability following compound exposure. Through my PhD, I developed a keen interest in the effects that pharmaceuticals and environmental compounds have on the DNA methylome and its possible links to classical genotoxic endpoints. Following on from my PhD I became a Research Associate at King’s College London, within the Environmental Carcinogenesis group headed by Professor David Phillips, where I continued along a similar vein of research focussing on establishing DNA mutational signatures of defined mutagens as part of the Mutographs of Cancer – CRUK Grand Challenge Project. As of 2021 I moved into industry taking on a Senior Scientist role in Genetic Toxicology at AstraZeneca where I support early in vitro assessment of genotoxicity. I have been a UKEMS member since 2015 and joined the NUKEMS committee in 2021.

I am a final year PhD student in the In Vitro Toxicology Group (IVTG) at Swansea University. My project is in collaboration with AstraZeneca and investigates the use of automated high-content imaging for in vitro genotoxicity testing. I obtained my Bachelor of Science and Masters in Toxicology from the University of Galway, Ireland. Before starting my PhD, I was a Toxicology Trainee in the Scientific Committee and Emerging Risks unit at the European Food Safety Authority (EFSA) Italy and worked as a Junior Toxicologist at Delphic HSE, UK.

I am a final year PhD student at Imperial College London in the Department of Metabolism, Digestion and Reproduction. My PhD is in collaboration with the genetic toxicology team at AstraZeneca and investigates the role of the cohesin complex and CTCF in genetic toxicology. I completed my Masters in Genomic Medicine at Imperial College while working in the Renal Research clinical trial team at the Royal Free Hospital before starting my PhD.

I am a PhD student at Swansea University with a project based in genetic toxicology and the development of quantitative Adverse Outcome Pathways using 3D liver models. I graduated from Swansea University with a BSc in biochemistry and genetics in 2020, after which I undertook an MRes investigating the gut microbiome and colorectal cancer. Following this, I worked as an innovation and research assistant in the Healthcare and Technology Centre in Swansea University supporting the delivery of healthcare related projects that collaborated academia and industry, and then moved on to the world of toxicology whereby I worked as a nanomedical research assistant. I am thoroughly enjoying my PhD project and keen to pursue a career in genetic toxicology, and I am pleased to have the opportunity to support other early career researchers.